Trade names from 'aranosa' to 'arifam®' - Electronic medicinal guide TALKDRUGS

Lyophilizate for the preparation of a solution for intravenous administration 0.5 g.

Capsules 50 mg and 100 mg.

Tablets, film-coated 50 mg, 100 mg.

Tablets coated with a coating, 50 mg or 100 mg.

Powder for suspension for oral administration, 25 mg / 5 ml.

Cream for external use 1%.
Boznalek, AO Bosnia and Herzegovina
Capsules with modified release 75 mg.
Capsules intestine soluble 75 mg.
Solution for intravenous administration of 20 mg / ml. 5 ml of the drug in ampoules of hydrolytic dark glass (type 1, USP). On the ampoule
Genfa Medica S.A. Switzerland
Lyophilizate for the preparation of a solution for intravenous administration, 40 mg.
Cream for external use 2%.

Liofilizate for the preparation of a solution for intravenous administration of 4 mg / complete with a solvent - sodium chloride solution 0.9%.

Concentrate for solution for infusion, 20 mg / ml.
Solution for subcutaneous and intravenous administration 2.5 mg / 0.5 ml.

Tablets, film-coated, 1 mg each.

AstraZeneca UK Ltd United Kingdom

Tablets are dispersible in the oral cavity 10 mg, 15 mg, 30 mg.

Tablets 5 mg, 10 mg, 15 mg, 30 mg.

Tablets, film-coated, 5 mg and 10 mg.

Tablets, film-coated, 5 mg, 10 mg.

Tablets, film-coated, 2.5 mg
Tablets, film-coated, 2.5 mg + 6.25 mg.

Tablets, film-coated, 5 mg + 6.25 mg and 10 mg + 6.25 mg.

Tablets with modified release, film-coated, 5 mg + 1.5 mg and 10 mg + 1.5 mg.